Pea Fibre | whatsinit

About

What it is and where it shows up.

Pea fibre is a dietary fibre ingredient derived from yellow peas (Pisum sativum L.), consisting mainly of pectin and hemicellulose with small amounts of protein; it is used in food products as a functional fibre source, texturiser, and bulking agent. It is obtained as a by-product of pea starch processing and is valued for its gut health, metabolic, and satiety benefits.

Safety summary

The regulatory and scientific consensus.

Pea fibre has a strong safety profile with no numerical ADI required; the EFSA FAF Panel (2025) concluded it raises no safety concern at proposed use levels for the general population. Manufacturing involves extensive heat treatment (>100°C for >40 min) that inactivates lectins, eliminating that concern. High intake may cause transient gastrointestinal symptoms (bloating, flatulence) typical of fermentable dietary fibres, particularly in individuals with IBS or IBD.

Regulatory landscape

What food-safety regulators have decided.

Jurisdiction	Status	Note
FSANZ (Food Standards Australia New Zealand) (Australia)	Approved	Pea fibre is permitted as a dietary fibre ingredient under the Australia New Zealand Food Standards Code; no specific maximum level prescribed. Classified as a food ingredient rather than a food additive.source
FSSAI (Food Safety and Standards Authority of India) (India)	Approved	Pea fibre is recognised as a dietary fibre ingredient under FSSAI regulations; peas and their derivatives are long-standing food ingredients in India. No specific standalone additive listing for pea fibre concentrate under FSS (Food Products Standards and Food Additives) Regulations 2011; permissible as a food ingredient consistent with general dietary fibre provisions.source
FDA (Food and Drug Administration) (United States)	Approved	Pea fibre (pea hull fibre) is recognised by the FDA as a dietary fibre under 21 CFR 101.9; it qualifies as an intrinsic or intact fibre from a whole food source. No specific maximum level set; used under GMP conditions.source
EFSA (European Food Safety Authority) (European Union)	Under_review	EFSA FAF Panel published safety opinion on FIPEA as a new food additive in March 2025 under Regulation (EC) No 1331/2008; concluded no safety concern at proposed use levels and no numerical ADI needed. Formal EU authorisation and listing under Regulation (EC) No 1333/2008 pending European Commission decision following the EFSA opinion.

Who should approach with care

Whose guidance would steer them away.

Ibs — As a fermentable dietary fibre, pea fibre may exacerbate bloating, flatulence, and altered bowel habits in individuals with Irritable Bowel Syndrome, particularly those following a low-FODMAP diet.

Ibd — During active flares of Inflammatory Bowel Disease (Crohn's disease or ulcerative colitis), high insoluble fibre intake including pea fibre may worsen gastrointestinal symptoms; medical guidance is recommended.

Infants — The EFSA FAF Panel noted that the contribution of FIPEA to total fibre intake in toddlers requires monitoring to remain within levels considered adequate by the NDA Panel; it is not recommended for infants under 12 months.

Other — Individuals with legume or pea allergy (Pisum sativum) should avoid pea fibre products, as residual pea proteins may trigger allergic reactions; FIPEA contains low but non-zero amounts of pea protein.

Research citations

The sources behind this verdict.

1EFSA. Safety evaluation of pea fibre concentrate (FIPEA) as food additive, 2025. efsa.europa.eu
2PubMed. Dietary Pea Fibre Improves Obesity, Intestinal Barrier, Reproductive Performance, Offspring Health of Parent Mice Deprived of Dietary Fibre, 2025. pmc.ncbi.nlm.nih.gov
3PubMed. A Comprehensive Review of Pea (Pisum sativum L.): Chemical Composition, Processing, Health Benefits, and Food Applications, 2023. ncbi.nlm.nih.gov
4PubMed. The Health Benefits of Dietary Fibre, 2020. pmc.ncbi.nlm.nih.gov
5PubMed. Evaluation of yellow pea fibre supplementation on weight loss and the gut microbiota: a randomized controlled trial, 2014. pmc.ncbi.nlm.nih.gov

Independently researched5 citations